# Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

> **NCT04543071** · PHASE2 · RECRUITING · sponsor: **Gulam Manji** · enrollment: 10 (estimated)

## Conditions studied

- Pancreatic Cancer
- Adenocarcinoma of the Pancreas
- Adenocarcinoma

## Interventions

- **DRUG:** Motixafortide
- **DRUG:** Cemiplimab
- **DRUG:** Gemcitabine
- **DRUG:** Nab paclitaxel

## Key facts

- **NCT ID:** NCT04543071
- **Lead sponsor:** Gulam Manji
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-09
- **Primary completion:** 2028-06
- **Final completion:** 2028-08
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-06-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04543071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04543071, "Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04543071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*